Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled, Phase 1 First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Doses of ABS-201 in Healthy Adult Participants With and Without Androgenetic Alopecia

Next Previous
Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Phase 1 First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Doses of ABS-201 in Healthy Adult Participants With and Without Androgenetic Alopecia

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 09 Sep 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ABS 201 (Primary) ; ABS 201 (Primary)
  • Indications Alopecia
  • Focus Adverse reactions; First in man; Proof of concept
  • Acronyms HEADLINE
  • Sponsors AbSci

Most Recent Events

  • 11 Aug 2026 According to an Absci media release, the MAD portion of the HEADLINE trial is ongoing, with participants with pattern hair loss (PHL) continuing to receive ABS-201. The company expects to report interim proof-of-concept data in the second half of 2026, followed by full proof-of-concept data in early 2027.
  • 24 Jun 2026 Positive interim results presented in the AbSci media release.
  • 07 May 2026 According to an Absci media release, company anticipates reporting preliminary safety, tolerability, and PK data in the second quarter of 2026.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top